The economic burden of switching targeted disease-modifying antirheumatic drugs among rheumatoid arthritis patients.
CONCLUSIONS: Switching to another tDMARD was associated with higher healthcare costs. Switching to abatacept, however, was associated with lower RA-related costs, fewer inpatient stays, but more frequent outpatient visits compared to switching to a TNFi.
PMID: 30653389 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Abatacept | Arthritis | Economics | Emergency Medicine | Health Insurance | Health Management | Healthcare Costs | Insurance | Orencia | Rheumatoid Arthritis | Rheumatology